Skip to main content

Table 1 Frailty category changes, therapeutic responses, and treatment discontinuation

From: Individualized dynamic frailty-tailored therapy (DynaFiT) in elderly patients with newly diagnosed multiple myeloma: a prospective study

 

All, N (%)

Fit, N (%)

Intermediate fit, N (%)

Frail, N (%)

Frailty category change

(N = 75)

(N = 30)

(N = 15)

(N = 30)

At least once

28 (37.3)

8 (26.7)

5 (33.3)

15 (50.0)a

At analysis

    

Improved

17 (22.7)

2 (13.3)

15 (50.0)

Deteriorated

8 (10.7)

6 (20.0)

2 (13.3)

Response

(N = 74)

(N = 30)

(N = 14)

(N = 30)

ORR

65 (87.8)

30 (100)

13 (92.9)

22 (73.3)

CR or sCR

40 (54.1)

18 (60.0)

9 (64.3)

13 (43.3)

VGPR

15 (20.3)

8 (26.7)

3 (21.4)

4 (13.3)

PR

10 (13.5)

4 (13.3)

1 (7.1)

5 (16.7)

MR

4 (5.4)

0 (0)

1 (7.1)

3 (10.0)

SD

5 (6.8)

0 (0)

0 (0)

5 (16.7)

Reason for TD

(N = 90)

(N = 33)

(N = 16)

(N = 41)

Non-hematologic AE, any

17 (18.9)

5 (15.2)

1 (6.3)

11 (26.8)

Grade 2

    

PNP-P

2 (2.2)

2 (6.1)

Grade 3

    

Pneumonia

1 (1.1)

1 (2.4)

Cerebral infarction

1 (1.1)

1 (2.4)

Grade 4

    

Pneumonia

5 (5.6)

1 (3.0)

4 (9.8)

Sepsis

4 (4.4)

1 (3.0)

3 (7.3)

Acute heart failure

1 (1.1)

1 (3.0)

Intercurrent death

    

Sudden death

2 (2.2)

1 (6.3)

1 (2.4)

Acute renal failure

1 (1.1)

1 (2.4)

Hematologic AE

    

Thrombocytopenia

1 (1.1)

1 (2.4)b

Reason other than AE, any

16 (17.8)

5 (15.2)

3 (18.8)

8 (19.5)

Deteriorating condition

4 (4.4)

1 (6.3)

3 (7.3)

Disease progression

3 (3.3)

1 (3.0)

1 (6.3)

1 (2.4)

Noncompliance

6 (6.7)

2 (6.1)

1 (6.3)

3 (7.3)

COVID-19

3 (3.3)

2 (6.1)

1 (2.4)

  1. Abbreviations: ORR, overall response rate; sCR, stringent complete response; CR, complete response; VGPR, very good partial response; PR, partial response; MR, minimal response; SD, stable disease; PFS, progression-free survival; OS, overall response; TD, treatment discontinuation; AE, adverse event; PNP-P, peripheral neuropathy grade 2 with pain.
  2. aIncluding four patients with age > 80 years.
  3. bTD because of cerebral hemorrhage secondary to thrombocytopenia.